As of mid-August 2026, CDC and WHO surveillance data show SARS-CoV-2 activity remains low globally, with emergency department visits at just 0.3% and only modest case increases in limited regions, far below pandemic thresholds. Current variants, including BA.3.2 (Cicada), exhibit limited immune escape and no evidence of markedly higher virulence or transmissibility sufficient to drive widespread surges. Enhanced post-2020 preparedness, including improved monitoring and vaccination programs, further anchors trader consensus at 96% against a new coronavirus pandemic this year. Realistic shifts could still arise from unexpected zoonotic spillovers or a rapidly evolving strain triggering exponential growth before year-end surveillance updates.